Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Introduction This study reviews the first 3 years of delivery of the first National Health Service (NHS)-commissioned trio rapid whole genome sequencing (rWGS) service for acutely unwell infants and ...

Most of 23andMe bought for a lot more than one could have thought–and why? Yesterday, the board of 23andMe confirmed that they have a court-approved definitive agreement for the sale of their core ...

Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe, according to Benzinga. The $256 ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.

Regeneron Pharmaceuticals REGN has emerged as the successful bidder in the bankruptcy auction for most of the assets of 23andMe Holding Co., a prominent player in human genetics and biotechnology.

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...